← Back to Search

Phosphodiesterase Type 5 Inhibitor

Tadalafil for Duchenne Muscular Dystrophy

Phase < 1
Waitlist Available
Led By Ronald Victor, MD
Research Sponsored by Cedars-Sinai Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 5 times over about 6 weeks
Awards & highlights

Summary

This study, supported by Parent Project Muscular Dystrophy, will determine if tadalafil or sildenafil can improve muscle blood flow during exercise in boys with Duchenne muscular dystrophy.

Eligible Conditions
  • Duchenne Muscular Dystrophy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~5 times over about 6-weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 times over about 6-weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Functional muscle ischemia
Secondary outcome measures
6 Minute Walk Test
Cardiac Function
EKG Monitoring
+2 more

Trial Design

2Treatment groups
Experimental Treatment
Group I: TadalafilExperimental Treatment1 Intervention
Group II: SildenafilExperimental Treatment1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tadalafil
FDA approved
Sildenafil
FDA approved

Find a Location

Who is running the clinical trial?

Cedars-Sinai Medical CenterLead Sponsor
503 Previous Clinical Trials
165,843 Total Patients Enrolled
Parent Project Muscular DystrophyOTHER
5 Previous Clinical Trials
10,996 Total Patients Enrolled
Ronald Victor, MDPrincipal InvestigatorCedars-Sinai Medical Center
6 Previous Clinical Trials
106 Total Patients Enrolled
~2 spots leftby Sep 2025